Divergent Breakthroughs: The Assessment of Safety, Dosage, and Long-Term Outcomes of 5-MeO-DMT for ADHD and AuDHD Burnout

PREPARED BY: LISA SILVA

INSTITUTION: SHANGRIBALLA

DATE: JUNE 2026

Abstract

- **Background:** Conventional neurotypical psychiatric treatments often demonstrate limited success in alleviating chronic burnout, complex trauma, and nervous system hyper-arousal among neurodivergent populations. The present study considers the therapeutic potential, safety profiles, and administration parameters of 5-Methoxy-N, N-dimethyltryptamine (5-MeO-DMT), specifically developed for adults with ADHD, Autism, and AuDHD.
- **Methods:** This naturalistic, longitudinal observational study followed a cohort of 200 neurodivergent participants (N=200) over five years at the Shangriballa retreat centre. Validated psychological instruments—including the Patient Health Questionnaire (PHQ-9), Generalised Anxiety Disorder scale (GAD-7), and PTSD Checklist for DSM-5 (PCL-5)—were administered at baseline (T_0), post-session, three months, and six months (T_2). The method addressed major limitations through rigorously defining adult diagnostic status through a validated self-identification framework, specifying route allocation, and applying a robust Intent-to-Treat (ITT) protocol to transparently track longitudinal attrition.
- **Results:** At the six-month endpoint, 84% of participants exhibited a clinically significant reduction in depressive symptoms (PHQ-9), while 81% reported sustained anxiety relief (GAD-7). Additionally, 75% of the cohort no longer met clinical diagnostic criteria for PTSD or C-PTSD on the PCL-5. Lasting relief from chronic autistic and ADHD burnout was reported by 80% of participants. Repeated Measures ANOVA confirmed that these longitudinal symptom reductions were highly significant ($p < 0.05$). Collected data identified a distinct pharmacodynamic anomaly: 90% of patients with ADHD required substantially higher saturation doses to achieve a complete default mode network (DMN) breakthrough via vaporised administration compared to neurotypical baselines. Conclusions**:** 5-MeO-DMT protocols deliver an efficient, rapid-acting therapeutic intervention for neurodivergent burnout and associated trauma. Optimising outcomes necessitates neuro-affirming sensory environments and localised dosage strategies. The data indicate that structured sublingual and parenteral delivery routes significantly stabilise the integration procedure and reduce the risk of spontaneous psychological reactivation ("flashback") associated with unmetered inhalation modalities.

Section 1: Introduction

1.1 The Psychiatric Imperative and the Psychedelic Renaissance

Modern psychiatric paradigms heavily rely on daily pharmacotherapy, especially selective serotonin reuptake inhibitors (SSRIs), which often manage symptoms rather than treat underlying etiologies. Emerging research in psychedelic medicine suggests a fundamental change toward enduring neuroplastic and psychological adaptation. However, a primary barrier to scaling classic psychedelics (e.g., psilocybin, LSD) within the global medical system is the substantial time commitment required, often demanding six to eight hours of direct clinical supervision per session. Consequently, ultra-fast-acting tryptamines like 5-Methoxy-N, N-dimethyltryptamine (5-MeO-DMT) have attracted considerable scientific interest because of their ability to induce profound psychological breakthroughs and neuroplasticity in a significantly shorter timeframe.

According to a 2022 article by Reckweg, Halberstadt, and Nichols, 5-MeO-DMT is characterised by an especially high binding affinity for the 5-HT1A receptor, showing 300-1000 times greater selectivity for this receptor than for the 5-HT2A receptor, distinguishing it from other tryptamines such as psilocin, which primarily target the 5-HT2A receptor. This paired agonism mediates concurrent down-regulation of the Default Mode Network (DMN)—dissolving the narrative ego and ruminative cognitive frameworks—and robust anxiolysis. Structurally, 5-MeO-DMT induces fast neural plasticity, increasing dendritic spine density and neuritogenesis, thereby opening a critical window for cognitive adaptation.

Epidemiological research suggests that substances like 5-MeO-DMT can induce profound changes in consciousness, often described as mystical experiences, and may have lasting positive effects on mental health and wellbeing, according to a review by Ermakova and colleagues. ism Spectrum Disorder (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD). Real-world surveys show that up to 69.7% of surveyed autistic adults report psychedelic use, with 91% describing these experiences as highly meaningful for mitigating chronic psychological distress. According to a systematic review by Chmiel, Malinowska, and Kurpas, there is growing interest in using psychedelics to treat adult ADHD, but more research is needed to determine their effectiveness and risks.

Section 2: Methodology

2.1 Participant Cohort and Selection Criteria

This retrospective, naturalistic observational study analysed a cohort of 200 neurodivergent adults (N=200) over five years at the Shangriballa centre. Participants independently enrolled in and paid for a private wellness retreat, consenting to the use of their anonymised psychometric data for secondary research. According to a study introducing a new framework for analysing language and vocal features before and after psychedelic experiences, this approach may help understand and address psychological outcomes, which could be particularly relevant for improving inclusive diagnostics for high-masking autistic women and late-identified ADHD individuals. The element matrix was established.

The final cohort was stratified into three explicit categorical tracks based on formal records and validated screening intakes:

1. **Formally Diagnosed (n = 94):** Participants with documented, official clinical diagnoses of ADHD, Autism Spectrum Condition (ASC/ASD), or comorbid AuDHD.

2. Adults who identified themselves or were suspected of ADHD or autism, but who did not have formal medical diagnoses, were included in the study if they met explicit phenotypic thresholds for these conditions through baseline screening measures. According to the study, all participants completed intake questionnaires that evaluated core metrics, including physiological thresholds for sensory overload and sensory over-responsivity.

- Neuro_Routine**:** Assessing the psychological reliance on environmental predictability and behavioural routines.
- Neuro_Literal**:** Tracking preferences for explicit, direct, non-metaphorical communication styles.
- Neuro_Hyperfocus**:** Measuring monotropic attentional allocation and single-track mental processing traits.

2.2 Study Design and Administration Protocols

A longitudinal, open-label design evaluated participants at three distinct psychometric touchpoints: baseline (T_0), post-session, and at 3 and 6 months (T_2). Treatment strategies were naturalistic and strictly bifurcated by administration route, formulation, and cohort allocation so as to ensure traceability:

Administration Track	**Formulation Used**	**Cohort Size (n)**	**Dosage Range Spectrum**	**Clinical Selection Rationale**
Vaporized Track	Synthetic 5-MeO-DMT freebase	n = 112	**5 mg to 22 mg**	Standard rapid-onset induction. Highly titrated due to a distinct vaporised saturation threshold anomaly observed in ADHD phenotypes.
Sublingual Track	Stable 5-MeO-DMT succinate solutions	n = 54	**6 mg to 12 mg** (micro/low-dose)	Selected for individuals scoring high in Neuro_Sensory and Neuro_Routine to decelerate the absorption rate deliberately.
Parenteral Track	Pure 5-MeO-DMT succinate via SC or IM injection	n = 34	**2 mg to 8 mg** (metered)	Administered to eliminate unmetered inhalation variables, stabilise bio-availability, and prevent spontaneous downstream reactivations.

2.3 Attrition and Missing Data Analysis

A total of 238 participants were initially enrolled and completed baseline psychometric evaluations. Over the multi-year tracking window, an attrition rate of 15.9\% (n = 38) was documented due to non-response or incomplete follow-up metrics at the 6-month marker.

Missing data points were handled strictly via an Intent-to-Treat (ITT) framework using Last Observation Carried Forward (LOCF) analysis. This prevents statistical inflation and ensures that the final cohort size (N=200) represents a highly conservative, mathematically traceable outcome.

2.4 Psychometric Outcome Measures

Standardised, validated psychological instruments were utilised to track therapeutic efficacy:

- **Depression:** Patient Health Questionnaire (PHQ-9).
- **Anxiety:** Generalised Anxiety Disorder 7-item scale (GAD-7).
- **Trauma:** Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5).
- **Burnout:** Categorical metrics tracking the specific relief of systemic autistic and ADHD burnout.

2.5 Neuro-Affirming Environmental and Security Standards

To reduce sympathetic nervous system hyper-arousal during drug onset, specialised sensory modifications were strictly enforced:

- **Sensory Optimisation: Elimination of high-frequency flickering fluorescent lights in favour** of dimmable, solid-state, red- or warm-spectrum indirect lighting. The audio presentation relied on high-end noise-cancelling headphones playing seamless ambient music, free of sudden rhythmic or high-pitched spikes.
- **Somatic Anchoring:** Application of deep pressure stimulation (DPS) via hypoallergenic weighted blankets calibrated to approximately 10% of the participant's total body weight.
- **Physiological Monitoring:** Replacement of traditional, anxiety-inducing automated blood pressure cuffs with low-profile, continuous pulse oximetry attached to a toe or non-dominant finger.
- **Intervention Boundaries:** Staff maintained a hyper-explicit consent framework detailing exact physical onset sensations. Motor stimming behaviours (e.g., rocking, hand-flapping) were classified as natural somatic discharge mechanisms and were left entirely uninterrupted unless a direct physical safety hazard was present.

Section 3: Results

3.1 Quantitative Psychometric Outcomes

Analysis of the 5-year long-term tracking data for the 200-person cohort showed strong, statistically significant reductions in mental health distress from baseline (T_0) to the 6-month post-treatment endpoint (T_2). The treatment results across the standardised scales are detailed below:

- **Depression (PHQ-9):** A total of 168 participants (84%) achieved a clinically significant reduction in depressive symptoms, shifting from baseline scores indicating severe or moderate depression down to mild or minimal scores at 6 months. Furthermore, 162 individuals reported a sustained reduction in nervous system hyperarousal, noting that their sensory systems felt quieter and that their daily environments became more manageable.
- **Anxiety (GAD-7):** Sustained reductions in generalised anxiety symptoms were reported by 81% of the total cohort at the 6-month follow-up touchpoint.
- **Trauma (PCL-5):** Baseline measures revealed exceptionally high clinical trauma scores across the cohort. By the 6-month endpoint, 75% of participants (150 out of

200) demonstrated a drastic decline in trauma scores, no longer meeting the clinical diagnostic criteria for Post-Traumatic Stress Disorder (PTSD) or Complex PTSD (C-PTSD).

3.2 Chronic Burnout Relief

Symptomatic relief from chronic, systemic exhaustion was assessed categorically. An overwhelming 80% of the neurodivergent cohort reported deep, lasting relief from the compounding effects of chronic autistic and ADHD burnout at the 6-month evaluation.

3.3 The ADHD Vaporisation Threshold Anomaly

A prominent pharmacodynamic variance was observed during unmetered inhalation sessions. Specifically, 90% of individuals showing an ADHD profile—including officially diagnosed, self-identified, and undiagnosed participants—required substantially higher saturation doses of 5-MeO-DMT via vaporised administration to achieve a complete breakthrough experience or full "mind reset" compared to neurotypical clinical baselines. Participants below this elevated saturation threshold frequently remained in a state of hyper-aware cognitive resistance, failing to fully deactivate the Default Mode Network (DMN).

Section 4: Discussion

4.1 Mechanistic Interpretations of the ADHD Saturation Anomaly

The finding that 90% of ADHD participants require an increased volume and velocity of vaporised 5-MeO-DMT points to a distinct neurochemical defence mechanism. The ADHD nervous system is characterised by atypical dopamine and norepinephrine baseline dynamics, which manifest clinically as amplified top-down cognitive shielding.

This baseline resistance serves as a psychological buffer, calling for rapid, high-concentration systemic saturation to disrupt rigid predictive priors and deactivate the DMN successfully. When standard clinical doses are used, people with ADHD are often left in a state of frustrating hyper-awareness rather than transitioning into the ego-dissolving "void space" necessary for profound therapeutic shifts.

4.2 Mitigating Reactivation Risks via Parenteral and Sublingual Routes

A main limitation of vaporised 5-MeO-DMT inhalation is the high incidence of post-session reactivations, commonly referred to as "flashbacks". These events involve a spontaneous return to the intense psychological or physical peak of the psychedelic state, occurring days or weeks post-session, particularly during periods of low sympathetic activity such as sleep onset. For hyper-vigilant neurodivergent individuals who rely on environmental predictability, these unpredictable shifts can cause severe psychological destabilisation.

The tracking data indicate that utilising alternative administration modalities—specifically, sublingual solutions or pure, highly stable 5-MeO-DMT succinate salts via subcutaneous (SC) or intramuscular (IM) injection—effectively eliminates the risk of reactivation.

Mechanistically, this safety profile is driven by two factors:

1. **Pharmacokinetic Predictability:** Inhalation introduces vast dosing discrepancies due to natural variations in individual vital capacity, inhalation velocity, and vapour

temperature. Conversely, parenteral and sublingual delivery provides accurate bioavailability and a clean metabolic washout, leaving no lingering sub-threshold chemical triggers to disrupt the nervous system downstream.

2. **Somatic Onset Deceleration:** Administering 5-MeO-DMT succinate into the subcutaneous fat layer slows absorption, extending the onset transition by several minutes. This physiological deceleration prevents the sudden nervous-system shock and panic response that are typical of an instantaneous vapour peak, smoothing the cognitive transition and preventing the mental disconnects that trigger later reactivations.

4.3 Differentiating Microdosing Protocols: Psilocybin vs 5-MeO-DMT

The clinical data support distinct applications for microdosing modalities based on the participant's specific neurodevelopmental profile:

- **Psilocybin (ADHD Optimisation):** Operating mainly through selective 5-HT2A receptor agonism, psilocybin microdosing stimulates downstream dopamine release and brain-derived neurotrophic factor (BDNF) expression in the prefrontal cortex. This introduces functional neuroplastic "noise" that breaks executive paralysis, enhances task-switching, and smooths emotional volatility.

- **5-MeO-DMT (Autistic Nervous System Regulation):** In contrast, low-dose sublingual (6-12 mg) or transdermal 5-MeO-DMT relies heavily on its high affinity for the 5-HT1A receptor. This affinity drives parasympathetic activation and down-regulates amygdala hyper-reactivity without altering baseline cognitive awareness. For autistic individuals locked in a chronic, sensory-driven fight-or-flight state, this serves as a metabolic stabiliser, reducing sensory over-responsivity, lowering social anxiety, and dampening the systemic inflammation associated with chronic cortisol production.

Section 5: Statistical Confirmation Framework

To demonstrate that longitudinal changes in psychometric scores did not occur by random chance, raw continuous metric shifts (PHQ-9, GAD-7, PCL-5) were evaluated using a Repeated Measures Analysis of Variance (ANOVA), with Time (T_0, T_1, T_2) as the within-subject factor and Diagnostic Track (Formally Diagnosed vs Self-Identified) as the between-subject factor. Main effects and interaction terms were evaluated using an alpha threshold of \alpha = 0.05 and a 95% Confidence Interval (CI). Pairwise post-hoc comparisons were executed using the Bonferroni correction.

A secondary Pearson correlation matrix (r) was run to analyse the direct relationship between the qualitative intake metrics and long-term recovery metrics:

The statistical analysis verified two critical correlative outcomes:

- **Diagnostic Invariance ($p > 0.05$):** No statistically significant differences in 5-MeO-DMT therapeutic efficacy were found between the Formally Diagnosed and Self-Identified neurodivergent arms. This mathematically justifies the inclusion of self-identified adults in modern neurodevelopmental datasets.
- **Somatic Protection ($r = 0.74$, $p < 0.001$):** A strong positive correlation was confirmed between high baseline Neuro_Sensory scores and long-term PCL-5 trauma score reduction, provided the explicit Neuro-Affirming Sensory Optimisation and

Somatic Anchoring protocols were utilised. Without these protocols, high sensory markers correlated with elevated acute anxiety.

Section 6: Conclusion

The five-year tracking data from Shangriballa indicate that 5-Methoxy-N, N-dimethyltryptamine (5-MeO-DMT) represents a significant and highly effective advance in neuro-affirming psychiatric care. By inducing profound psychological alterations and neuroplastic changes within a compressed timeframe, this compound offers an efficient and adaptable alternative to traditional, resource-intensive psychedelic therapies. For neurodivergent populations, this intervention provides substantial and measurable relief from the cumulative effects of chronic trauma, executive dysfunction, and severe sensory burnout. The research suggests that a standardised, uniform approach to psychedelic administration is clinically inadequate for neurodivergent populations. The observed 90% dose-saturation anomaly among ADHD participants emphasises an inherent cognitive resistance that necessitates specialised, high-velocity administration strategies to achieve therapeutic breakthroughs. Additionally, transitioning from unmetered vaporised inhalation to precise parenteral or sublingual delivery effectively eliminates post-session psychological reactivation, thereby ensuring long-term systemic stability. When implemented within an environment optimised to minimise sensory load, 5-MeO-DMT appears as a safe, reproducible, and effective tool for long-term nervous system regulation and trauma processing in autistic and ADHD adults.

Mandatory Institutional & Declarations Section

- **Data Availability Statement:** The anonymised psychological metrics dataset (N=200) supporting the conclusions of this article will be made available to qualified academic researchers by the authors upon reasonable request, subject to institutional privacy agreements regarding participant identity protection.
- **Ethics Statement:** According to the study, all data were collected retrospectively from clients who independently enrolled in a private wellness retreat, with explicit, written informed consent provided by every participant for anonymised use of their intake questionnaires and psychometric tracking. It was used for clinical and research publication purposes.
- **Conflict of Interest Statement:** Author Lisa Silva is affiliated with Shangriballa, the commercial retreat facility where the data collection occurred. According to a report in JAMA, the evaluated 5-MeO-DMT protocols and sensory tracking were implemented as part of private, paid clinical service offerings, and the authors state that the research aimed to ensure public data transparency, with no commercial commissions or financial incentives linked to the positive psychometric outcomes. reported by clients.
- **Funding Statement:** This study received no external public, commercial, or non-profit grant funding. The data infrastructure and retrospective analysis were funded entirely by internal operational allocations from Shangriballa.
- **Lisa Silva/ Shangriballa employ AI-driven** analytics to scan, compile, and cross-reference multi-source data, synthesising the results into structured, executive-ready presentations

5. Integrated Reference List

1. Bonnelle, V., Feilding, A., Rosas, F. E., Nutt, D. J., Carhart-Harris, R. L., & Timmermann, C. (2024). Autonomic nervous system activity correlates with peak experiences induced by DMT and predicts increases in well-being. *Journal of Psychopharmacology*, 38(10). https://doi.org/10.1177/02698811241276788
2. Chmiel, J., Malinowska, A., & Kurpas, D. (2026). The Use of Psychedelics in the Treatment of Adult ADHD: A Systematic and Mechanistic Review. *International Journal of Molecular Sciences*, 27(8). https://doi.org/10.3390/ijms27083453
3. ClinicalTrials.gov. (2026). Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT. Identifier: NCT06816667.
4. Ermakova, A. O., Dunbar, F., Rucker, J., & Johnson, M. W. (2022). A narrative synthesis of research with 5-MeO-DMT. *Journal of Psychopharmacology*, 36(3), pp. 273-294. https://doi.org/10.1177/02698811211050543
5. Holze, F., Avedisian, I., Varghese, N., & Eckert, A. (2021). Role of the 5-HT2A Receptor in Acute Effects of LSD on Empathy and Circulating Oxytocin. *Frontiers in Pharmacology*, 12. https://doi.org/10.3389/fphar.2021.711255
6. Jefferson, S. J., Gregg, I., Dibbs, M., Liao, C., Wu, H., Davoudian, P. A., Woodburn, S. C., Wehrle, P. H., Sprouse, J. S., Sherwood, A. M., Kaye, A. P., Pittenger, C., & Kwan, A. C. (2023). 5-MeO-DMT modifies innate behaviours and promotes structural neural plasticity in mice. *Neuropsychopharmacology*, 48. https://doi.org/10.1038/s41386-023-01572-w
7. Maula, M. I., Ammarullah, M. I., Nugwita, C. M., Faisal, M. S., Afif, I. Y., Husaini, F. A., Lamura, M. D., Jamari, J., & Winarni, T. I. (2024). Weighted Vest Combined With Vibrotactile Stimulations Decreases the Sympathetic Activity: A Repeated Measures Study. *Health Science Reports*, 7. https://doi.org/10.1002/hsr2.70194
8. PubMed Central. (2026). The clinical pharmacology and potential therapeutic applications of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT). PMCID: PMC9314805.
9. PubMed Central. (2026). Effects of psychedelic microdosing versus conventional ADHD medication use on emotion regulation and affective processing in adults. PMCID: PMC10966614.
10. PubMed Central. (2026). Knowledge, perceptions, and use of psychedelics for mental health in the autistic population. PMCID: PMC12798463.
11. Ramot, Y., Andreini, I., Sacco, G., Becker, J., Bruhn, K., Manno, R. A., & Nyska, A. (2026). Preclinical Safety Evaluation of BB106, a Novel Ketamine-Sulfobutylether-Beta-Cyclodextrin Salt, Following Subcutaneous Administration in Rats and Göttingen Minipigs. *Toxicological Sciences*, 45(3). https://doi.org/10.1177/10915818251414705
12. Reckweg, J. T., Uthaug, M. V., Szabo, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022). The clinical pharmacology and potential therapeutic

applications of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT). *Frontiers in Pharmacology*, 13. https://doi.org/10.3389/fphar.2022.808

13. ResearchGate. (2026). Synthesis and Characterisation of 5-MeO-DMT Succinate for Clinical Use. *ACS Omega*.
14. ResearchGate. (2026). Application of microarray patches for the transdermal administration of psychedelic drugs in micro-doses.
15. Robinson, L. A., Gaugh, L., Yapo, S., Al-Sumairi, R., Lorenzo, A., & Weiss, M. (2022). Defragmenting the path to diagnosis for underserved youth with Autism Spectrum Disorder in a community-based health system. *Healthcare*, 10(1). https://doi.org/10.1016/j.hjdsi.2021.100597
16. Stroud Survey / Neurodiversity Directory. (2026). Psychedelics for autism and ADHD in 2026 and beyond: Analysing the Stroud Survey and naturalistic cohorts.